Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKALO-2: tersolisib with CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer
CTR20255191Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tersolisib in breast cancer, sponsored by Eli Lilly and Company. Started Jun 2026; status: active.
02
Drugs
tersolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20255191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255191.